tsc-200-a0201
·Code: TSC-200-A0201
tsc-200-a0201: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| TScan Therapeutics, Inc. (TCRX) | Phase 1 |
Clinical Trials (1)
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Frequently asked questions
Who is developing tsc-200-a0201?
tsc-200-a0201 is being developed by TScan Therapeutics, Inc..
How many clinical trials involve tsc-200-a0201?
BioSniper tracks 1 clinical trial involving tsc-200-a0201.
Get deeper analysis on tsc-200-a0201
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis